NL300343I1 - 6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel - Google Patents

6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel

Info

Publication number
NL300343I1
NL300343I1 NL300343C NL300343C NL300343I1 NL 300343 I1 NL300343 I1 NL 300343I1 NL 300343 C NL300343 C NL 300343C NL 300343 C NL300343 C NL 300343C NL 300343 I1 NL300343 I1 NL 300343I1
Authority
NL
Netherlands
Prior art keywords
alpha
furanylcarboxyl
androst
difluoro
diene
Prior art date
Application number
NL300343C
Other languages
English (en)
Other versions
NL300343I2 (nl
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300343(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0019172.6A external-priority patent/GB0019172D0/en
Priority claimed from GBGB0108800.4A external-priority patent/GB0108800D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL300343I1 publication Critical patent/NL300343I1/nl
Publication of NL300343I2 publication Critical patent/NL300343I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
NL300343C 2000-08-05 2008-04-15 6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1,4-dieen-17-carbothionzuur-s-fluormethylester als een ontsteking-remmend middel NL300343I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0019172.6A GB0019172D0 (en) 2000-08-05 2000-08-05 Novel compounds
GBGB0108800.4A GB0108800D0 (en) 2001-04-07 2001-04-07 Novel compounds
PCT/GB2001/003495 WO2002012265A1 (en) 2000-08-05 2001-08-03 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT

Publications (2)

Publication Number Publication Date
NL300343I1 true NL300343I1 (nl) 2008-06-02
NL300343I2 NL300343I2 (nl) 2008-09-01

Family

ID=26244792

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300343C NL300343I2 (nl) 2000-08-05 2008-04-15 6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1,4-dieen-17-carbothionzuur-s-fluormethylester als een ontsteking-remmend middel

Country Status (36)

Country Link
US (3) US7498321B2 (nl)
EP (5) EP2348032B1 (nl)
JP (3) JP4436041B2 (nl)
KR (3) KR100889426B1 (nl)
CN (4) CN100513416C (nl)
AP (1) AP1422A (nl)
AR (3) AR032361A1 (nl)
AT (2) ATE380194T1 (nl)
AU (4) AU7576001A (nl)
BG (1) BG66241B1 (nl)
BR (2) BR0113039A (nl)
CA (3) CA2417826A1 (nl)
CO (2) CO5310534A1 (nl)
CY (4) CY1107899T1 (nl)
CZ (2) CZ2003353A3 (nl)
DE (3) DE122008000029I1 (nl)
DK (3) DK1305329T4 (nl)
DZ (1) DZ3468A1 (nl)
EA (1) EA005992B1 (nl)
ES (4) ES2546830T3 (nl)
FR (1) FR08C0014I2 (nl)
HK (2) HK1056180B (nl)
HU (3) HU230328B1 (nl)
IL (4) IL154148A0 (nl)
LU (1) LU91429I2 (nl)
MA (1) MA25899A1 (nl)
MX (2) MXPA03001097A (nl)
NL (1) NL300343I2 (nl)
NO (4) NO324747B1 (nl)
NZ (2) NZ523957A (nl)
OA (1) OA12394A (nl)
PL (2) PL359917A1 (nl)
PT (3) PT2348032E (nl)
SI (3) SI1305329T2 (nl)
SK (1) SK287576B6 (nl)
WO (2) WO2002012266A1 (nl)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
EP2348032B1 (en) * 2000-08-05 2015-07-15 Glaxo Group Limited 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
MXPA03009940A (es) 2001-04-30 2004-01-29 Glaxo Group Ltd DERIVADOS ANTI-INFLAMATORIOS DE 17. BETA-CARBOTIOATO ESTER DE ANDROSTANO CON UN GRUPO DE ESTER CICLICO EN LA POSICIoN 17.ALFA.
EP1395604B1 (en) * 2001-06-12 2008-06-25 Glaxo Group Limited Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0202216D0 (en) * 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
US20050152845A1 (en) * 2002-02-04 2005-07-14 Keith Biggadike Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
AU2003205855A1 (en) * 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
US6928877B2 (en) * 2002-05-24 2005-08-16 Symyx Technologies, Inc. High throughput microbalance and methods of using same
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
IL153462A0 (en) * 2002-12-16 2003-07-06 Chemagis Ltd Thiocarboxylic acid organic salts and processes utilizing the same
EP1611149A1 (en) * 2003-04-04 2006-01-04 Alpharma APS Process for the preparation of steroidal carbothioic acid derivatives and intermediates
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
GB0323701D0 (en) * 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
HUE026134T2 (en) 2004-08-23 2016-05-30 Mannkind Corp Microparticles containing diketopiperazine salts for drug delivery
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
WO2007017670A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
ES2640282T3 (es) 2005-09-14 2017-11-02 Mannkind Corporation Método de formulación de fármacos basado en el aumento de la afinidad de superficies de micropartículas cristalinas para agentes activos
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
CA2646578A1 (en) * 2006-03-22 2007-10-18 3M Innovative Properties Company Novel formulations
EA200801854A1 (ru) * 2006-03-22 2009-04-28 Глаксо Груп Лимитед Новые композиции
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
GB0612027D0 (en) 2006-06-16 2006-07-26 Glaxo Group Ltd Novel process
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2046787B1 (en) 2006-08-01 2011-04-06 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
EA016199B1 (ru) 2007-01-10 2012-03-30 Айрм Ллк Соединения и композиции как ингибиторы активирующей канал протеазы
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EA200901082A1 (ru) 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
AR069637A1 (es) 2007-12-10 2010-02-10 Novartis Ag Derivados de pirazinas
TW200944540A (en) 2007-12-21 2009-11-01 Schering Corp C20-C21 substituted glucocorticoid receptor agonists
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
IL279542B2 (en) 2008-06-13 2023-10-01 Mannkind Corp Dry powder inhaler and drug delivery system
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8148353B2 (en) * 2008-08-07 2012-04-03 Plus Chemicals Sa Polymorphs of fluticasone furoate and process for preparation thereof
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
WO2010025236A1 (en) * 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102272104B (zh) 2008-12-30 2014-07-09 帕尔马根治疗(炎症)有限公司 用于治疗呼吸疾病的磺酰胺化合物
MX2011007499A (es) 2009-01-13 2011-08-04 Glaxo Group Ltd Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
LT2400950T (lt) 2009-02-26 2019-08-26 Glaxo Group Limited Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2408798A1 (en) 2009-03-19 2012-01-25 Plus Chemicals S.A. Polymorphs of fluticasone furoate and processes for preparation thereof
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521763A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
RU2543716C2 (ru) 2009-04-23 2015-03-10 Тереванс Рэспирэйтори Кампани Эл Эл Си Диамидные соединения, обладающие активностью антагониста мускаринового рецептора и активностью агониста в2 адренергического рецептора
TW201103892A (en) 2009-04-24 2011-02-01 Glaxo Group Ltd Compounds
US20120035237A1 (en) 2009-04-24 2012-02-09 Diane Mary Coe Pyrazole and triazole carboxamides as crac chann el inhibitors
MA33304B1 (fr) 2009-04-30 2012-05-02 Glaxo Group Ltd Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
EP2467141B1 (en) 2009-08-17 2018-10-31 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
PT105138B (pt) * 2010-06-01 2012-11-06 Hovione Farmaciencia S A Método para a preparação de compostos orgânicos monofluorometilados biologicamente activos
PT105139B (pt) * 2010-06-01 2013-01-29 Hovione Farmaciencia S A Método para a monofluorometilação de substratos orgânicos para preparação de compostos orgânicos biologicamente activos
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
WO2012009609A1 (en) 2010-07-15 2012-01-19 Battelle Memorial Institute Biobased polyols for potential use as flame retardants in polyurethane and polyester applications
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
AU2014200770B2 (en) * 2010-08-31 2015-11-12 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JP5792307B2 (ja) * 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
JP2013536835A (ja) * 2010-09-01 2013-09-26 カディラ・ヘルスケア・リミテッド プロピオン酸／フロ酸フルチカゾンを調製するための方法
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
US9156791B2 (en) 2010-10-21 2015-10-13 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CN102558273B (zh) * 2010-12-14 2014-07-02 浙江省天台县奥锐特药业有限公司 氟替卡松糠酸酯的制备方法
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
AP2013007103A0 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as TRK inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
PT105723B (pt) * 2011-05-26 2014-03-24 Hovione Farmaci Ncia S A Método para a preparação de compostos orgânicos biologicamente activos
BR112013031570A2 (pt) 2011-06-08 2017-03-21 Glaxo Group Ltd inalador de pó seco.
KR20140041699A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
MX354163B (es) 2012-07-12 2018-02-15 Mannkind Corp Sistemas y métodos de suministro de fármaco en polvo seco.
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP3007697B1 (en) 2013-06-14 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac1 inhibitors for inducing bronchodilation
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
RU2016112266A (ru) 2013-10-17 2017-11-20 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
ES2667424T3 (es) 2014-04-24 2018-05-10 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
CA2948441A1 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
EP3148521B1 (en) 2014-05-28 2019-12-18 GlaxoSmithKline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
CN108066329B (zh) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 一种吸入用氟替卡松或其衍生物的微粒的制备方法
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
TWI679279B (zh) * 2018-05-09 2019-12-11 臺中榮民總醫院 檢測成人發作型史笛兒氏症之罹病風險及預後之方法
JPWO2019235616A1 (ja) 2018-06-08 2021-06-17 東興薬品工業株式会社 フルチカゾンフランカルボン酸エステル点鼻組成物
CA3103679A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
US11304901B2 (en) 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
US20220306617A1 (en) 2019-08-28 2022-09-29 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR580494A (fr) 1923-07-10 1924-11-07 Const Metalliques Schiltigheim Procédé d'établissement des buses d'aération ou autres tuyaux
US2169265A (en) 1939-05-02 1939-08-15 City Novelty Corp Linked ornamental chain
US2837464A (en) 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
DE1059906B (de) 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US2816902A (en) † 1957-01-14 1957-12-17 Schering Corp Hydroxylated steroids
US3067197A (en) 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
GB1047518A (en) 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB1158492A (en) 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
US3639434A (en) 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
IT1061787B (it) 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
GB1227992A (nl) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
IT1034011B (it) 1969-06-26 1979-09-10 Vister Vismara Terapeutici S P Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
BE788444A (fr) * 1971-09-06 1973-01-02 Sumitomo Chemical Co Procede de production de 2,5-dimethyl-2,4-hexadiene
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3808080A (en) * 1972-06-08 1974-04-30 Bronson Instr Inc Ultrasonic seaming apparatus
US3989686A (en) 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en) 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
DE2336693A1 (de) 1973-07-19 1975-02-06 Nassheuer Ind Ofenbau Jean Strahlheizrohr
US4093721A (en) 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
GB1517278A (en) 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
YU54476A (en) 1975-03-31 1982-05-31 Taisho Pharmaceutical Co Ltd Process for obtaining 17-ester 21-halo-pregnane
DE2538569A1 (de) 1975-08-29 1977-03-03 Siemens Ag Verfahren zur metallisierung von duroplasten
CH628355A5 (de) 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4198403A (en) 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
US4263289A (en) 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4188385A (en) 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4261984A (en) 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
DE2817988A1 (de) 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en) 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267173A (en) 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1291A (en) 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
SE449106B (sv) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
ZA814440B (en) 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4861765A (en) 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
ATE90355T1 (de) 1987-10-13 1993-06-15 Nicholas S Bodor Weiche steroide mit anti-entzuendungswirkung.
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
FR2644787B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
US5202316A (en) 1989-03-22 1993-04-13 Roussel Uclaf N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
FR2644788B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
JPH07116215B2 (ja) 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
JPH04506066A (ja) 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4025342A1 (de) 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5250293A (en) 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
TW247878B (nl) 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
EP0633776B1 (en) 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0689424B1 (en) 1993-03-17 1998-10-14 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
DE4328819A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
JPH08291073A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
JPH08291072A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
US5707984A (en) 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
KR19990076859A (ko) 1995-12-29 1999-10-25 그레이엄 브레레톤, 레슬리 에드워즈 17.베타.-카르복시, 카르보티오 및 아미드 안드로스탄 유도체의락톤 유도체
US5985862A (en) 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5981517A (en) 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
DE69918422T2 (de) 1998-03-14 2005-08-11 Altana Pharma Ag Phthalazinone als PDE3/4 Inhibitoren
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
GEP20053474B (en) 1999-04-30 2005-03-25 Pfizer Prod Inc Glucocorticoid Receptor Modulators
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
EP2348032B1 (en) * 2000-08-05 2015-07-15 Glaxo Group Limited 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ES2305029T3 (es) 2000-12-22 2008-11-01 Nippon Shinyaku Co., Ltd. Agente preventivo/terapeutico para enfermedades inflamatorias del tracto respiratorio.
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
JP3691459B2 (ja) 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7244742B2 (en) 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic

Also Published As

Publication number Publication date
HUP0303354A2 (hu) 2004-01-28
NL300343I2 (nl) 2008-09-01
AR032471A1 (es) 2003-11-12
WO2002012266A1 (en) 2002-02-14
ES2317922T3 (es) 2009-05-01
HUP0303354A3 (en) 2012-12-28
US7101866B2 (en) 2006-09-05
EP1305329B1 (en) 2007-12-05
BRPI0113042B1 (pt) 2018-02-14
US20040028615A1 (en) 2004-02-12
KR20030071751A (ko) 2003-09-06
HK1056181A1 (zh) 2004-02-06
CA2417825C (en) 2008-07-22
CY1107899T1 (el) 2010-07-28
EP2348032B1 (en) 2015-07-15
PT1305329E (pt) 2007-12-24
CN1680423A (zh) 2005-10-12
DE122008000029I1 (de) 2009-05-20
CN1468253A (zh) 2004-01-14
IL188364A (en) 2012-05-31
CY1116845T1 (el) 2017-03-15
MXPA03001097A (es) 2003-05-27
CN1294142C (zh) 2007-01-10
DE60131750T3 (de) 2015-07-30
SI1305329T2 (sl) 2015-07-31
EP1775305A3 (en) 2012-08-22
IL154148A (en) 2008-07-08
EP2067784A2 (en) 2009-06-10
NZ523957A (en) 2004-12-24
DK1305329T3 (da) 2008-02-04
PT1775305E (pt) 2014-11-24
DE60131750T2 (de) 2008-11-06
ES2546830T3 (es) 2015-09-29
EP2348032A2 (en) 2011-07-27
DK1775305T3 (en) 2014-11-17
EP1305330B1 (en) 2008-12-03
CY2008009I1 (el) 2009-11-04
EP1775305B1 (en) 2014-09-17
NO333467B1 (no) 2013-06-17
CA2634715A1 (en) 2002-02-14
EP1305330A1 (en) 2003-05-02
ATE416184T1 (de) 2008-12-15
HK1056180B (zh) 2008-07-25
AP1422A (en) 2005-06-05
SK1422003A3 (en) 2003-06-03
AR032361A1 (es) 2003-11-05
ATE380194T1 (de) 2007-12-15
NO2008006I1 (no) 2008-06-23
NO2008006I2 (no) 2011-07-04
KR20070118317A (ko) 2007-12-14
HUS1600012I1 (hu) 2018-05-28
FR08C0014I1 (nl) 2008-05-30
CN1468252A (zh) 2004-01-14
LU91429I2 (fr) 2008-06-16
AU7576001A (en) 2002-02-18
IL154148A0 (en) 2003-07-31
EP2067784A3 (en) 2012-08-22
CN1315867C (zh) 2007-05-16
MXPA03001096A (es) 2003-05-27
BG107518A (bg) 2003-09-30
PT2348032E (pt) 2015-10-14
SI2348032T1 (sl) 2015-10-30
CO5310534A1 (es) 2003-08-29
DE60131750D1 (en) 2008-01-17
FR08C0014I2 (fr) 2009-10-30
CN1680425A (zh) 2005-10-12
US20030199485A1 (en) 2003-10-23
NO324747B1 (no) 2007-12-03
US7498321B2 (en) 2009-03-03
AU2001276497B2 (en) 2005-04-07
LU91429I9 (nl) 2019-01-02
AP2003002731A0 (en) 2003-03-31
OA12394A (en) 2004-07-09
EP1775305A2 (en) 2007-04-18
IL188364A0 (en) 2008-03-20
NO20030550D0 (no) 2003-02-04
CZ304043B6 (cs) 2013-09-04
HK1056180A1 (en) 2004-02-06
AU7649701A (en) 2002-02-18
EP1305329A1 (en) 2003-05-02
NO20075376L (no) 2007-10-22
DE60136818D1 (en) 2009-01-15
CY2008009I2 (el) 2009-11-04
ES2523930T3 (es) 2014-12-02
ES2292604T5 (es) 2015-06-01
EA200300082A1 (ru) 2003-08-28
CN100513416C (zh) 2009-07-15
NO20030549D0 (no) 2003-02-04
PL359999A1 (en) 2004-09-06
BR0113042A (pt) 2003-07-08
IL154175A0 (en) 2003-07-31
ES2292604T3 (es) 2008-03-16
US20080317833A1 (en) 2008-12-25
HU230328B1 (hu) 2016-02-29
AR063555A1 (es) 2009-02-04
CY1116145T1 (el) 2017-02-08
EP2348032A3 (en) 2012-08-22
DK2348032T3 (en) 2015-08-24
EP1305329B2 (en) 2015-03-18
KR100827379B1 (ko) 2008-05-07
PL213373B1 (pl) 2013-02-28
KR100889426B1 (ko) 2009-03-23
KR20030028806A (ko) 2003-04-10
EA005992B1 (ru) 2005-08-25
CN1294141C (zh) 2007-01-10
PL359917A1 (en) 2004-09-06
JP5150607B2 (ja) 2013-02-20
CO5310550A1 (es) 2003-08-29
BRPI0113042B8 (pt) 2021-05-25
NO20030550L (no) 2003-04-04
BG66241B1 (bg) 2012-08-31
CA2417825A1 (en) 2002-02-14
NO20030549L (no) 2003-02-04
SK287576B6 (sk) 2011-03-04
MA25899A1 (fr) 2003-10-01
SI1305329T1 (sl) 2008-04-30
JP2004505990A (ja) 2004-02-26
DK1305329T4 (da) 2015-06-15
NZ523958A (en) 2004-11-26
BR0113039A (pt) 2003-07-15
CZ2003353A3 (cs) 2003-05-14
CA2417826A1 (en) 2002-02-14
SI1775305T1 (sl) 2015-01-30
HUP0303084A2 (hu) 2003-12-29
DZ3468A1 (fr) 2002-02-14
AU2001275760B2 (en) 2005-03-17
JP2010077145A (ja) 2010-04-08
WO2002012265A1 (en) 2002-02-14
JP4436041B2 (ja) 2010-03-24
JP2004505989A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
NL300343I1 (nl) 6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel
ITTO20000779A0 (it) Composizioni farmaceutiche.
ITTO20010005A1 (it) Formulazione farmaceutica.
IS6858A (is) Trísólpýridín sem bólgueyðandi efni
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
DK1524266T3 (da) Farmaceutisk sammensætning
ITMI20010748A0 (it) Composizioni farmaceutiche
MXPA03001425A (es) Compuestos farmaceuticos.
NO20026123L (no) Farmasöytiske sammensetninger
NO20001294D0 (no) Måler for skyvekraft
NO20031095L (no) Farmasoytiske sammensetninger
NO20023976D0 (no) Endoparasittisidisk middel
DE60129445D1 (de) Quinolin-derivate als antientzündungsmittel
DE60221342D1 (de) Niedrig substituierte Hydroxypropylzellulose
MXPA03001857A (es) Composicones medicinales.
IT1317827B1 (it) Composizioni solventi.
EE200200689A (et) Ravimkoostised
ES1047994Y (es) Tirachinas perfeccionado.
ES1048047Y (es) Hucha perfeccionada.
IT1319677B1 (it) Composizione funghicida.
ES1045197Y (es) Babero perfeccionado.
ES1046505Y (es) Sacacorchos perfeccionado.
ES1045138Y (es) Tarima perfeccionada.
ES1045345Y (es) Cubitera perfeccionada.
ES1048035Y (es) Mosquitera perfeccionada.